146 related articles for article (PubMed ID: 34953401)
1. Preloading magnesium attenuates cisplatin-associated nephrotoxicity: pilot randomized controlled trial (PRAGMATIC study).
Suppadungsuk S; Phitakwatchara W; Reungwetwattana T; Pathumarak A; Phakdeekitcharoen B; Kitiyakara C; Srisuwarn P; Davenport A; Nongnuch A
ESMO Open; 2022 Feb; 7(1):100351. PubMed ID: 34953401
[TBL] [Abstract][Full Text] [Related]
2. Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: which dose is more suitable?
Ilhan Y; Onder AH; Ozbay MF; Karakaya G; Sezgin Goksu S; Ozturk B; Coskun HS
Eur Rev Med Pharmacol Sci; 2024 May; 28(9):3403-3413. PubMed ID: 38766796
[TBL] [Abstract][Full Text] [Related]
3. Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: a retrospective study.
Yoshida T; Niho S; Toda M; Goto K; Yoh K; Umemura S; Matsumoto S; Ohmatsu H; Ohe Y
Jpn J Clin Oncol; 2014 Apr; 44(4):346-54. PubMed ID: 24503028
[TBL] [Abstract][Full Text] [Related]
4. Renal protective effect of a hydration supplemented with magnesium in patients receiving cisplatin for head and neck cancer.
Kimura T; Ozawa T; Hanai N; Hirakawa H; Suzuki H; Hosoi H; Hasegawa Y
J Otolaryngol Head Neck Surg; 2018 Feb; 47(1):10. PubMed ID: 29394952
[TBL] [Abstract][Full Text] [Related]
5. Risk and impact of delayed renal impairment in patients with locally advanced head and neck squamous cell carcinoma receiving chemoradiotherapy with cisplatin.
Patimarattananan T; Nongnuch A; Pattaranutaporn P; Unwanatham N; Jiarpinitnun C; Ngamphaiboon N
Support Care Cancer; 2021 Feb; 29(2):877-887. PubMed ID: 32524284
[TBL] [Abstract][Full Text] [Related]
6. Short hydration with 20 mEq of magnesium supplementation for lung cancer patients receiving cisplatin-based chemotherapy: a prospective study.
Hase T; Miyazaki M; Ichikawa K; Yogo N; Ozawa N; Hatta T; Ando M; Sato M; Kondo M; Yamada K; Hasegawa Y
Int J Clin Oncol; 2020 Nov; 25(11):1928-1935. PubMed ID: 32740717
[TBL] [Abstract][Full Text] [Related]
7. Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin.
van der Vorst MJDL; Neefjes ECW; Toffoli EC; Oosterling-Jansen JEW; Vergeer MR; Leemans CR; Kooistra MP; Voortman J; Verheul HMW
BMC Cancer; 2019 Nov; 19(1):1066. PubMed ID: 31703649
[TBL] [Abstract][Full Text] [Related]
8. Incidence of Severe Nephrotoxicity With Cisplatin Based on Renal Function Eligibility Criteria: Indirect Comparison Meta-analysis.
Dahal A; Bellows BK; Sonpavde G; Tantravahi SK; Choueiri TK; Galsky MD; Agarwal N
Am J Clin Oncol; 2016 Oct; 39(5):497-506. PubMed ID: 24824144
[TBL] [Abstract][Full Text] [Related]
9. Understanding the Risk Factors and Long-Term Consequences of Cisplatin-Associated Acute Kidney Injury: An Observational Cohort Study.
Bhat ZY; Cadnapaphornchai P; Ginsburg K; Sivagnanam M; Chopra S; Treadway CK; Lin HS; Yoo G; Sukari A; Doshi MD
PLoS One; 2015; 10(11):e0142225. PubMed ID: 26556481
[TBL] [Abstract][Full Text] [Related]
10. Effect of Silymarin Administration on Cisplatin Nephrotoxicity: Report from A Pilot, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.
Shahbazi F; Sadighi S; Dashti-Khavidaki S; Shahi F; Mirzania M; Abdollahi A; Ghahremani MH
Phytother Res; 2015 Jul; 29(7):1046-53. PubMed ID: 25857366
[TBL] [Abstract][Full Text] [Related]
11. Magnesium supplementation therapy to prevent cisplatin-induced acute nephrotoxicity in pediatric cancer: a randomized phase-2 trial.
Matsui M; Makimoto A; Chin M; Koh K; Tomotsune M; Kaneko T; Morikawa Y; Hamada R; Yuza Y
Int J Clin Oncol; 2024 May; 29(5):629-637. PubMed ID: 38564107
[TBL] [Abstract][Full Text] [Related]
12. Hydration with 15 mEq Magnesium Is Effective at Reducingthe Risk for Cisplatin-induced Nephrotoxicity in Patients Receiving Cisplatin (≥50 mg/m2) Combination Chemotherapy.
Yamamoto Y; Watanabe K; Tsukiyama I; Yabushita H; Matsuura K; Wakatsuki A
Anticancer Res; 2016 Apr; 36(4):1873-7. PubMed ID: 27069173
[TBL] [Abstract][Full Text] [Related]
13. Magnesium protects against cisplatin-induced acute kidney injury by regulating platinum accumulation.
Solanki MH; Chatterjee PK; Gupta M; Xue X; Plagov A; Metz MH; Mintz R; Singhal PC; Metz CN
Am J Physiol Renal Physiol; 2014 Aug; 307(4):F369-84. PubMed ID: 24944268
[TBL] [Abstract][Full Text] [Related]
14. Magnesium protects against cisplatin-induced acute kidney injury without compromising cisplatin-mediated killing of an ovarian tumor xenograft in mice.
Solanki MH; Chatterjee PK; Xue X; Gupta M; Rosales I; Yeboah MM; Kohn N; Metz CN
Am J Physiol Renal Physiol; 2015 Jul; 309(1):F35-47. PubMed ID: 25947343
[TBL] [Abstract][Full Text] [Related]
15. Electrolytes supplementation can decrease the risk of nephrotoxicity in patients with solid tumors undergoing chemotherapy with cisplatin.
Minzi OMS; Lyimo TE; Furia FF; Marealle AI; Kilonzi M; Bwire GM; Malichewe C
BMC Pharmacol Toxicol; 2020 Sep; 21(1):69. PubMed ID: 32967726
[TBL] [Abstract][Full Text] [Related]
16. Retrospective Analysis of Cisplatin Nephrotoxicity in Patients With Head and Neck Cancer Receiving Outpatient Treatment With Concurrent High-dose Cisplatin and Radiotherapy.
Faig J; Haughton M; Taylor RC; D'Agostino RB; Whelen MJ; Porosnicu Rodriguez KA; Bonomi M; Murea M; Porosnicu M
Am J Clin Oncol; 2018 May; 41(5):432-440. PubMed ID: 27281266
[TBL] [Abstract][Full Text] [Related]
17. Pre-treatment risk factors to predict early cisplatin-related nephrotoxicity in locally advanced head and neck cancer patients treated with chemoradiation: A single Institution experience.
Cavalieri S; Platini F; Barretta F; Nuzzolese I; Ottini A; Bergamini C; Resteghini C; Colombo E; Iacovelli NA; Franceschini M; Calareso G; Di Pede P; De Feo G; Gandelli M; Toffolatti L; Guglielmo M; Ripamonti CI; Cosmai L; Licitra L; Alfieri S
Oral Oncol; 2023 Nov; 146():106579. PubMed ID: 37778228
[TBL] [Abstract][Full Text] [Related]
18. High-dose IV magnesium in mesothelioma patients receiving surgery with hyperthermic intraoperative cisplatin: Pilot studies and design of a phase II randomized clinical trial.
Gupta S; Wells SL; Jose AM; Seitter RH; Feghali L; Devaraj N; Hartigan PM; Yacoubian S; Kwiatkowski DJ; Burke DM; Barlow J; Bueno R; Leaf DE
J Surg Oncol; 2023 Dec; 128(7):1141-1149. PubMed ID: 37702402
[TBL] [Abstract][Full Text] [Related]
19. Long-term renal follow-up of children treated with cisplatin, carboplatin, or ifosfamide: a pilot study.
McMahon KR; Harel-Sterling M; Pizzi M; Huynh L; Hessey E; Zappitelli M
Pediatr Nephrol; 2018 Dec; 33(12):2311-2320. PubMed ID: 30218190
[TBL] [Abstract][Full Text] [Related]
20. Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity.
Saito Y; Kobayashi M; Yamada T; Kasashi K; Honma R; Takeuchi S; Shimizu Y; Kinoshita I; Dosaka-Akita H; Iseki K
Support Care Cancer; 2017 Feb; 25(2):481-487. PubMed ID: 27699503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
